# A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

> **NCT02550652** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 126 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Mycophenolate Mofetil/Mycophenolic Acid
- **DRUG:** Obinutuzumab
- **OTHER:** Placebo
- **DRUG:** Methylprednisolone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02550652
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-13
- **Primary completion:** 2019-01-15
- **Final completion:** 2023-08-02
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02550652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02550652, "A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02550652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*